Search research articles
Contact Us
Filters
Showing results (61-70 of 80) with videos related to
Page
of 8
Sort By:
International Journal of Molecular Sciences
|
September 20, 2019
PGE<sub>1</sub>-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood
Daniel Christoph Amberger, Fatemeh Doraneh-Gard, Carina Gunsilius, et al.
International Journal of Molecular Sciences
|
August 12, 2022
Generation of Leukaemia-Derived Dendritic Cells (DC<sub>leu</sub>) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations
Christoph Schwepcke, Lara Kristina Klauer, Diana Deen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
Andreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood
|
December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid, Myriam Labopin, Arnon Nagler, et al.
International Journal of Molecular Sciences
|
January 8, 2023
Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes
Elias Rackl, Lin Li, Lara Kristina Klauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
Hans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL
Matthias Stelljes, Simon Raffel, Nael Alakel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Molecular Immunology
|
September 21, 2024
Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo
Elias Rackl, Anne Hartz, Hazal Aslan Rejeski, et al.
The New England Journal of Medicine
|
September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
Andreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 80) with videos related to
Sort By:
Page
of 8
International Journal of Molecular Sciences
|
September 20, 2019
PGE<sub>1</sub>-Containing Protocols Generate Mature (Leukemia-Derived) Dendritic Cells Directly from Leukemic Whole Blood
Daniel Christoph Amberger, Fatemeh Doraneh-Gard, Carina Gunsilius, et al.
International Journal of Molecular Sciences
|
August 12, 2022
Generation of Leukaemia-Derived Dendritic Cells (DC<sub>leu</sub>) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations
Christoph Schwepcke, Lara Kristina Klauer, Diana Deen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial
Andreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Blood
|
December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid, Myriam Labopin, Arnon Nagler, et al.
International Journal of Molecular Sciences
|
January 8, 2023
Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes
Elias Rackl, Lin Li, Lara Kristina Klauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial
Hans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2023
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL
Matthias Stelljes, Simon Raffel, Nael Alakel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Volker Diehl, et al.
Molecular Immunology
|
September 21, 2024
Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo
Elias Rackl, Anne Hartz, Hazal Aslan Rejeski, et al.
The New England Journal of Medicine
|
September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
Andreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Page
of 8